arrow
C

Chong-Jen Yu

National Taiwan University Hospital
H指数:89
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Epigenetic reprogramming of T cell metabolism restores function and enhances anti-tumor immunity in lung cancer

表观遗传重编程T细胞代谢恢复功能并增强肺癌的抗肿瘤免疫

2026-05-120
PRE
Safety and immunogenicity of one or two additional doses of the adjuvanted recombinant zoster vaccine administered 5–6 years after primary vaccination in adults ≥50 years

在≥50岁成人中,加强接种一剂或两剂佐剂重组带状疱疹疫苗5~6年后的安全性与免疫原性

2026-05-040
OA
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52

Nivolumab联合化疗和贝伐单抗治疗TASUKI-52非鳞NSCLC患者的4年预后

2026-01-290
OAAI
Continuous positive airway pressure effects on energy expenditure, intake, hormonal regulation, and body composition: a randomized trial

持续气道正压通气对能量消耗、摄入、激素调节和身体成分的影响:一项随机试验

SLEEP
IF4.9
2025-09-011
OAAI
Association of T-cell immunoglobulin and mucin domain-3 gene (TIM3) polymorphism with susceptibility and severity of Mycobacterium avium complex lung disease: a prospective study in Taiwan.

T细胞免疫球蛋白和黏蛋白域-3基因(TIM3)多态性与鸟分枝杆菌复合体肺部疾病易感性和严重程度的相关性:一项在台湾进行的前瞻性研究。

2025-08-200
OAAI
Exploring the protective effects of Huangyangning dispersible tablets against Doxorubicin-induced cardiotoxicity based on UHPLC-Q-TOF-MS/MS, network pharmacology, molecular docking and experimental validation in vivo and in vitro

基于UHPLC-Q-TOF-MS/MS、网络药理学、分子对接以及体内体外实验验证,探究黄杨宁分散片对多柔比星诱导的心脏毒性的保护作用。

2025-08-060
PRE
Effects of CPAP on Sleep Regularity, Attention, and 24-Hour Ambulatory Blood Pressure Variability: A Randomized Controlled Trial

持续气道正压通气对睡眠规律性、注意力和24小时动态血压变异性的影响:一项随机对照试验

SLEEP
IF4.9
2025-05-190
PRE
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial

一线纳武利尤单抗联合铂类化疗和贝伐珠单抗治疗晚期非鳞非小细胞肺癌:TASUKI-52 III期随机试验3年随访

2025-03-010
PRE
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis

Atezolizumab,bevacizumab,培美曲塞和铂类用于EGFR TKI失败后的EGFR突变NSCLC患者: 免疫细胞谱分析的II期研究

2024-12-230
OA